Pharmaceutical Market Europe • June 2025 • 41
APPOINTMENTS
MC2 Therapeutics
Trine Ahlgreen
MC2 Therapeutics has appointed Trine Ahlgreen as chief executive officer. Ahlgreen has an extensive background spanning commercial leadership of global, regional and local pharmaceutical product launches, leadership of several cross-functional teams and business development across Europe, the US and Japan. She most recently served as chief business officer at Micreos Pharmaceuticals and previously held roles of increasing responsibility over more than 20 years at Novo Nordisk, culminating in her position as senior business unit director, diabetes in Denmark and Iceland. During her time at Novo Nordisk, Ahlgreen also served as GLP-1 diabetes business unit head, Europe region, as well as global marketing director, Victoza brand team and global marketing director, future devices.
iOnctura
Michelle Tsai
iOnctura has appointed Michelle Tsai as chief operating officer. Tsai has significant experience in oncology and specialty pharmaceuticals, and takes on the role after serving on iOnctura’s commercial advisory board. She was also previously vice president, international commercial and early commercial lead at Sumitomo Pharma Switzerland, and held roles at Novartis.
Delphia Therapeutics
Reza Mazhari
Delphia Therapeutics has appointed Reza Mazhari as chief business officer. Mazhari joins Delphia from Triana Biomedicines, where he also served as chief business officer. Previously, he was head of search and evaluations for oncology at Novartis, and vice president of translational medicine and head of business development and licensing at Rexahn Pharmaceuticals.
Nucleome Therapeutics
Bhavna Hunjan
Nucleome Therapeutics has appointed Bhavna Hunjan as chief business officer. Hunjan joins the company from C4X Discovery, where she most recently served as chief business officer and board director. Bhavna was also previously senior strategy manager at Cancer Research UK, and held positions at Lehman Brothers, Nomura International and PwC.
Enara Bio
Stacey Davis
Enara Bio has appointed Stacey Davis as chief business officer and chief financial officer. Davis brings more than 25 years of industry experience to the role and joins Enara from Xilio Therapeutics, where she served as chief business officer. Previously, she held multiple senior leadership roles at Novartis Oncology, Johnson & Johnson and Prominex.
OneChain Immunotherapeutics
Barbara Krebs-Pohl
OneChain Immunotherapeutics has appointed Barbara Krebs-Pohl as chair of its board of directors. Krebs-Pohl holds over 27 years of industry experience and currently serves as managing director at Viopas Venture Consulting. She also previously held multiple positions at MorphoSys, culminating in her role as chief business officer and executive committee member.
Commit Biologics
Paul Parren
Commit Biologics has appointed Paul Parren as a member of its scientific advisory board. Parren, a molecular immunologist, holds more than 25 years of industry experience and previously spent over 15 years at Genmab, where he headed preclinical research and development. He is a co-founder and chief scientific officer of Gyes and its two spin-out companies.
TauRx Pharmaceuticals
Michael Cooper
TauRx Pharmaceuticals has appointed Michael Cooper as an independent non-executive director. Cooper currently serves as an internal consultant in the Office for Life Sciences for the UK government, and previously held positions in Trinity Delta and Edison Investment Research, where he was head of research, healthcare.
Slingshot Therapeutics
Ed Savory
Slingshot Therapeutics has appointed Ed Savory as head of chemistry. Savory holds over 22 years of experience in advancing drug development programmes and joins Slingshot from BenevolentAI, where he most recently served as senior vice president, drug discovery. He has also held several roles at Proximagen and Cambridge Biotechnology.
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services